Novigenix is a molecular diagnostics company specializing in liquid biopsy tests for early detection of cancer and precision medicine. Its technology is based on gene expression profiles of circulating blood cells and tumor-derived protein markers in combination with mathematical analytical models. The company offers Colox, a molecular blood test designed to reduce mortality from colorectal cancer through early detection and follow-up colonoscopy.